Acthar Gel

[anonymous]

Your statement is incorrect. Questcor did spend a great deal on the product from a GMP standpoint, significantly upgrading the manufacturing process. The FDA did not make Questcor go back and "do the studies". In fact, the FDA granted Questcor the indication for West's Syndrome based upon existing data. At the same time, Questcorvoluntarily dismissed several of the existing indications, including gout. Another thing you fail to mention is that, prior to the acquisition by Questcor, there was virtually no use of Acthar. They created the market in MS relapse and West's Syndrome, but could not sustain the business model based upon expensive manufacturing process and low volume (and they were not the first company to experience this). With the price increase came patient assistance programs. Yes, you can argue that the price increase was egregious, but it made Acthar much more available to patients by reducing their out of pocket costs (to zero in many cases). Criticize all you want, but use facts, not hysterical rhetoric.

Horsecrap. When Sanofi-Aventis sold the drug back in 2001, the price was less than $150/vial. In the 15 years since that time, Questcor didn't do a damned thing with it but mark it up every year and sell it for everything despite crappy data supporting its clinical effectiveness. FDA made Questcor go back and do the studies because the original approval was so flimsy.

So do tell us how much research they actually did to prove it was worth marking up the drug over 150 times more than it was? NONE.

 

[anonymous]

......Valeant .....Mylan...... looks like Mallinckrodt is in GOOD COMPANY

add Lannett to mix